Transcription Profiling CXR Biosciences is pioneering the application of transcription profiling in investigative toxicology.
Transcription profiling measures drug or chemical induced changes in gene expression within each affected tissue providing a unique tool for defining biological pathways that are affected by toxins. CXR examines changes across the whole genome of the species under test in parallel, which provides a very powerful tool for Investigative Toxicology, especially in situations where there is little existing knowledge of the toxic mechanisms involved. We can also compare the mechanisms of toxicity in discrete cell populations within a single tissue (e.g. leydig cells and sertoli cells of the testes) by using laser capture microdissection (LCM) coupled with pressure pulse catapulting to isolate individual cell types prior to extracting the mRNA for transcription profiling. Transcription profiling can also be used in mechanistic toxicology to elucidate cellular events underlying drug toxicity. Comparison of the changes in gene expression with those of known toxicants or other compounds, can be used to characterise new compounds, engineer out toxic moieties, and be of benefit in lead candidate selection. It can also be used to identify biomarkers for toxicity screening and to verify pharmacodynamic endpoints in clinical trials. CXR Biosciences can :- AGILENT GENE ARRAY TECHNOLOGY
At CXR we have chosen to use the Agilent gene array technology as it is a flexible and sensitive microarray platform that facilitates analysis of small amounts of RNA, which is useful when analysing LCM dissected tissue. CXR Biosciences is the only company in the UK, and is only the second in Europe to have obtained accreditation from Agilent and be awarded 'Certified Aglilent Service Provider' status. The stringent accreditation criteria demanded by Agilent reflects the high quality of service and expertise at CXR. BACK
|
